Fresenius SE & Co KGaA (FRE.HM)
| Previous close | 28.04 |
| Open | 28.17 |
| Bid | 28.73 x 0 |
| Ask | 28.76 x 0 |
| Day's range | 28.17 - 28.50 |
| 52-week range | 24.00 - 31.15 |
| Volume | |
| Avg. volume | 819 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
UPDATE 2-Fresenius raises outlook on strong quarterly results, exits Vamed
German healthcare group Fresenius first-quarter results beat expectations, the company said on Wednesday, citing strong performance at its Kabi and Helios businesses, prompting it to raise its full-year outlook. First-quarter earnings before interest and tax (EBIT) were 633 million euros ($680 million), above analysts' expectations of 606 million euros, according to a consensus of forecasts from Vara Research. In a bid to get leaner, Fresenius also said that it would sell its investment unit, Fresenius Vamed, completing its portfolio restructuring.
BloombergFresenius Sells Controlling Stake in Vamed Rehab Business to PAI
(Bloomberg) -- Fresenius SE has agreed to sell a controlling stake in the rehabilitation business of its Vamed unit to French private equity firm PAI Partners as the German healthcare company further trims its portfolio.Most Read from BloombergSaudi Arabia Steps Up Arrests Of Those Attacking Israel OnlineTurkey Confirms All Trade Halt With Israel Over War in GazaHuawei Secretly Backs US Research, Awarding Millions in PrizesBiden Calls Ally Japan ‘Xenophobic’ Along With China, RussiaIn Jamie Dimo
Simply Wall St.Institutions own 30% of Fresenius SE & Co. KGaA (ETR:FRE) shares but retail investors control 43% of the company
Key Insights Fresenius SE KGaA's significant retail investors ownership suggests that the key decisions are influenced...
